NASDAQ:MRTX - Mirati Therapeutics, Inc.
$63.27
 $1.04
+1.67%
4:00PM EDT
2019-04-18
Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing a pipeline of targeted oncology products. The Company's clinical pipeline consists of three product candidates: MGCD265, MGCD516 and mocetinostat. MGCD265 and MGCD516 are orally-bioavailable, spectrum-selective kinase inhibitors. Both MGCD265 and MGCD516 are in development to treat patients with non-small cell lung cancer (NSCLC), and other solid tumors. MGCD265 is in Phase Ib clinical development and MGCD516 is in the dose escalation phase of Phase I clinical development. Mocetinostat is an orally-bioavailable, spectrum-selective histone deacetylase (HDAC), inhibitor, which is in Phase II development. Mocetinostat is being developed for the second line treatment of patients with bladder cancer and non-hodgkins lymphoma (NHL), specifically focusing on diffuse large B-cell lymphoma (DLBCL), and follicular lymphoma (FL). Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  MRTX     avg for
industry  
  avg for
sector  
42 stocks weight:  172. 27   203. 85   241. 91  
42 stocks rank:  1. 42 K 1. 44 K 1. 05 K
# analyst opinions:  13. 00   14. 51   13. 97  
mean recommendation:  2. 00   2. 09   2. 01  

quick ratio:  8. 62   5. 27   1. 81  
current ratio:  8. 67   5. 62   2. 25  

target price low:  60. 00   84. 80   115. 21  
target price avg:  82. 23   111. 51   137. 51  
target price high:  110. 00   135. 81   157. 84  
1-yr high:  78. 95   114. 23   138. 78  
last close:  63. 27   87. 66   116. 69  
50-day avg:  71. 99   95. 54   123. 44  
200-day avg:  55. 43   94. 25   121. 11  
1-yr low:  28. 15   72. 78   98. 34  
volume:  366. 12 K 4. 11 M 8. 07 M
50-day avg volume:  611. 70 K 2. 76 M 5. 02 M
200-day avg volume:  611. 40 K 2. 92 M 4. 59 M

1-day return:  1. 67 % -0. 41 % 0. 07 %
this week return:  -4. 18 % -5. 74 % -4. 11 %
12-wk return:  -5. 28 % 1. 61 % -0. 05 %
52-wk return:  119. 51 % 3. 12 % 8. 78 %

enterprise value (EV):  2. 01 B 48. 94 B 114. 64 B
market cap:  2. 23 B 43. 07 B 104. 73 B
EBITDA:  -102. 45 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -19. 59   4. 22   12. 73  
enterprise/revenue (EV/R):  155. 25   63. 17   12. 84  
total revenue:  12. 93 M 10. 62 B 38. 47 B
total debt:  0. 00   12. 24 B 16. 73 B
net income (common):  -98. 42 M 2. 20 B 4. 20 B

shares outstanding:  35. 27 M 571. 70 M 1. 24 B
shares:  25. 24 M 571. 81 M 1. 23 B
shares short:  5. 09 M 10. 17 M 13. 00 M
shares short prior month:  4. 55 M 9. 54 M 17. 33 M
short ratio:  6. 96   5. 41   3. 28  
total cash/share:  6. 37   11. 14   9. 33  
total cash:  224. 63 M 6. 71 B 7. 15 B
free cash flow:  -34. 44 M 3. 58 B 2. 96 B
operating cash flow:  -70. 10 M 4. 15 B 4. 30 B

book value:  6. 20   12. 78   26. 92  
price/book:  10. 21   3. 06   -1. 74  
gross profits:  12. 93 M 8. 04 B 34. 86 B
operating margins:  -793. 96 % -725. 35 % -89. 04 %
EBITDA margins:  0. 00 % 10. 94 % 22. 51 %
profit margins:  0. 00 % 7. 81 % 10. 57 %
gross margins:  100. 00 % 37. 08 % 55. 70 %

1-yr max volatility:  18. 40 % --- ---
1-yr mean volatility:  0. 39 % 0. 03 % 0. 04 %

1-yr EPS:  -3. 19   2. 40   4. 10  
forward EPS:  -4. 49   3. 97   7. 13  
P/E:  -19. 86   13. 63   22. 72  
forward P/E:  -14. 09   -15. 95   13. 99  
PE/G:  5. 71   -1. 65   -1. 32  
growth:  -3. 48 % 127. 12 % 29. 61 %
earnings high:  -0. 88   1. 00   1. 66  
earnings avg:  -0. 95   0. 77   1. 53  
earnings low:  -1. 03   0. 50   1. 39  
revenue high:  -0. 00   2. 68 B 10. 78 B
revenue avg:  -0. 00   2. 59 B 10. 57 B
revenue low:  -0. 00   2. 49 B 10. 36 B
return on assets:  -33. 26 % -2. 75 % 4. 55 %
return on equity:  -57. 08 % -18. 45 % 5. 46 %
revenue/share:  0. 42   13. 29   55. 46  

beta (1yr vs S&P500):  1. 59   1. 25   0. 93  
sharpe (1yr):  1. 54   0. 37   0. 70  

held % insiders:  0. 92 % 6. 39 % 3. 38 %
held % institutions:  110. 78 % 78. 14 % 68. 52 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-21 : MRTX
.    + 4.769 =         4.769 :: INITIAL WEIGHT
.   + 34.081 =         38.85 :: inverse volume-to-price addition
.   + 44.853 =        83.703 :: spline projection addition
.    x 1.766 =       147.784 :: 13 weeks' performance factor
.    x 2.197 =       324.662 :: one-year gains+dividend factor
.    x 1.431 =       464.729 :: industry recommendation factor
.     x 2.27 =      1054.767 :: symbol recommendation factor
.    x 1.457 =       1537.27 :: EV/R factor
.    x 0.997 =      1532.157 :: return on assets factor
.    x 0.994 =      1523.412 :: return on equity factor
.    x 2.459 =      3745.516 :: current ratio factor
.    x 1.064 =      3983.681 :: quick ratio factor
.    x 1.069 =      4260.264 :: short ratio factor
.    x 2.211 =      9419.908 :: price-to-book factor
.    x 1.156 =     10891.712 :: 5-day avg > 200-day avg
.    x 1.299 =     14146.477 :: 50-day avg > 200-day avg
.    x 1.663 =     23523.243 :: P/E weight
.    x 0.647 =     15214.963 :: PE/G factor
.    x 1.465 =     22288.645 :: beta factor
.    x 1.537 =     34256.875 :: sharpe factor
.    x 0.977 =     33478.081 :: target low factor
.    x 1.182 =     39586.932 :: target mean factor
.    x 1.086 =     42989.062 :: target high factor
.     x 1.31 =     56310.852 :: industry 2-weeks return factor
.    x 0.928 =      52270.85 :: "drift" penalty 1 days ago
.    x 0.995 =     52013.165 :: overall "drift" factor
.    x 0.816 =     42440.598 :: largest single-day jump factor
.     x 1.01 =     42863.354 :: mean volatility factor
.    x 1.098 =     47042.852 :: 42-day mean volatility factor
.      x 1.0 =     47035.216 :: factor hist industry gain for week 16
.   cubeRoot =        36.097 :: reduced to standardize
.  + 136.169 =       172.266 :: add/subtract for performance
.                    172.266 :: FINAL WEIGHT for NASDAQ:MRTX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org